Annovis Bio, Inc.
NYSE:ANVSBiotechnology
+$0.00 today
- Market cap
- $51.64M
- Beta
- 1.24
- P/E (TTM)
- -1.1
- EPS (TTM)
- -$1.47
Volume 1.35M
Average 1.08M
ANVS Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Annovis Bio, Inc.NYSE: ANVS
Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026
Cash & equivalents falls 36.1% from a year ago
Cash & equivalents stood at $14.22M at the end of Q1 FY2026, down 36.1% from a year earlier and down 27.2% from the prior quarter. Over 3 fiscal years it compounded at -11.7% a year.
Context
- Cash & equivalents amounted to 87.5% of total assets at the end of Q1 FY2026, up 4.4 pp from a year earlier.
- Cash & equivalents increased in 2 of the last 3 fiscal years.
What to watch
Whether cash & equivalents keeps falling in the next quarterly balance sheet after a -36.1% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 19.53M USD
- Year-over-year change
- +85.1%
- 4-year CAGR
- -19.1%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 19.53M | +85.1% |
| FY2024 | 2024-12-31 | 10.55M | +83.4% |
| FY2023 | 2023-12-31 | 5.75M | -79.7% |
| FY2022 | 2022-12-31 | 28.38M | -37.9% |
| FY2021 | 2021-12-31 | 45.69M | — |
Cash & Equivalents vs competitors
How ANVS compares with its peers on the latest reported figures
- ANVS's Mar 2026 cash & equivalents of $14.22M is the 4th highest of the 6 companies compared; the peer median is $21.66M.
- Its year-over-year change of -36.1% is the 4th highest of 6, against a peer median of +216.8%.
- Cash & equivalents amounts to 87.5% of total assets for ANVS, versus a peer median of 87.8%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $36.47M | -39.1% | -23.9% | 90.8% | |
| Mar 2026 | $34.41M | +216.8% | +824.7% | 97.4% | |
| Mar 2026 | $21.66M | -45.8% | -28.7% | 87.8% | |
| Mar 2026 | $14.22M | -36.1% | -11.7% | 87.5% | |
| Mar 2026 | $9.08M | +299.7% | -9.2% | 47.4% | |
| Dec 2025 | $6.18M | +736.7% | -23.8% | 5.8% | |
| Peer median (excluding ANVS) | $21.66M | +216.8% | -23.8% | 87.8% | |
Competitors are the stored peer set for ANVS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Annovis Bio, Inc.
NYSE:ANVS
Intrinsic Alpha fair value
Locked
Current Price
$1.21
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.